C4 THERAPEUTICS INC. - COMMON STOCK

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

14 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

08 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

08 Dec 2024 12:30:00 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

20 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

31 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

28 Oct 2024 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

15 Oct 2024 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

09 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

30 Sep 2024 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

13 Sep 2024 10:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

10 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

08 Sep 2024 18:05:00 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Participate in Upcoming September Investor Conferences

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation

14 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

01 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

16 Jul 2024 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

08 Jul 2024 07:00:00 By Nasdaq GlobeNewswire